Search

Interdisciplinary approach to CKM care

Explore the global impact of Cardiovascular- Kidney- Metabolic (CKM) syndrome, and the need for an integrated approach to manage these interconnected conditions. Insights from experts at Boehringer Ingelheim and George Washington University.

Innovating for our business

We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.

EASi-HF™ Phase III trial in patients with HFpEF

Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.

EASi-KIDNEY™ Phase III trial for people with CKD

Boehringer Ingelheim's Sandy Sommer on how treatment innovations in CKD can also improve care for connected conditions, including heart failure.

Translating Human Pharma Science into Animal Health Innovation

Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health

Our Venture Fund on the search for groundbreaking trends

The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.

collaboration criving innovation

In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.

Celebrating 20 years of Metacam for cattle

Celebrating 20 years of Metacam (Meloxicam) for cattle

Facts about the INPULSIS™ trials

Boehringer Ingelheim half-year results 2023

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Boehringer Ingelheim strong growth pipeline acceleration 2023

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Building Successful Partnerships in Animal Health

Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.

Reimagining digital healthcare worldwide

How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes

Targeting HER2 in cancer: The story of zongertinib

We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC

Circular economy: Taking action to reduce plastic waste

The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation

2024 half year results innovation progress

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

collaboration-kings-college-london

Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia

1885-1948: Innovative beginnings

The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products

1990-2023: Value through Innovation

The Boehringer Ingelheim history from 1990 to 2023, with milestones

Phase II trial results in people living with obesity or overweight

Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas

Ukraine Help: The heroes of Mainz-Finthen

Travis Kelley helps Olena and Wasyl flee from Ukraine. This is the record of a dramatic and emotional rescue operation.

Uncommon_Mutations_Database

New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use

Boehringer Ingelheim advances SIRP immune-oncology program

Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

Breakthrough Designation granted in US and China

SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers